RT Journal Article
T1 Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
A1 Ramos-Rincon, Jose-Manuel
A1 López-Carmona, María-Dolores
A1 Cobos-Palacios, Lidia
A1 López-Sampalo, Almudena
A1 Rubio-Rivas, Manuel
A1 Martín-Escalante, María-Dolores
A1 de-Cossio-Tejido, Santiago
A1 Taboada-Martínez, María-Luisa
A1 Muiño-Miguez, Antonio
A1 Areses-Manrique, Maria
A1 Martinez-Cilleros, Carmen
A1 Tuñón-de-Almeida, Carlota
A1 Abella-Vázquez, Lucy
A1 Martínez-Gonzalez, Angel-Luís
A1 Díez-García, Luis-Felipe
A1 Ripper, Carlos-Jorge
A1 Asensi, Victor
A1 Martinez-Pascual, Angeles
A1 Guisado-Vasco, Pablo
A1 Lumbreras-Bermejo, Carlos
A1 Gómez-Huelgas, Ricardo
A1 On Behalf Of The Semi-Covid-Network, 
K1 COVID-19
K1 SARS-CoV-2
K1 Spain
K1 age ≥ 80
K1 mortality
K1 remdesivir
AB (1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p
SN 2077-0383
YR 2022
FD 2022-06-29
LK http://hdl.handle.net/10668/21309
UL http://hdl.handle.net/10668/21309
LA en
DS RISalud
RD Apr 11, 2025